Still, many analysts on Wall Street think the correction is way overdone. Regeneron's stock could soar by 50% in the next ...

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

changing its mind in guidance for the multiple sclerosis and eczema drugs. NICE had previously rejected Roche's Ocrevus (ocrelizumab) for multiple sclerosis and Sanofi's Dupixent (dupilumab) ...

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action. The company’s head of external innovation and ...

“Somewhere between 7, 8, 10% of kids will have episodic and some of them rather severe and chronic eczema,” said Russell Libby ... While systemic treatments like dupilumab (Dupixent; Sanofi and ...

After years of delays and debate, 2024 was the year when several health initiatives started to move forward. And advocates ...

Eczema symptoms can be mild — a small patch of itchy, dry, red or pink textured skin — or they can be severe, Dr. Shasa Hu, associate professor in the department of dermatology and cutaneous surgery ...

By Stephen Beech A new way of treating common inflammatory skin conditions such as eczema is on the horizon, according to a new study. American researchers discovered that a compound ...

A daily cream containing a GluK2-activating compound could therefore be a promising way to prevent several inflammatory skin conditions.

New data reveals that longer-term lebrikizumab treatment significantly improves outcomes for patients with moderate-to-severe atopic dermatitis who didn’t meet response criteria by week 16.

Medically reviewed by Jurairat J. Molina, MD Dermatitis is a group of skin problems related to genes, environment, and ...